Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Pfizer and Innovent agreed to a licensing, co-development, and co-commercialization partnership across a portfolio of antibody-drug conjugates. Innovent will co-commercialize in the U.S. and Europe and share profits, while retaining rights in Greater China. The deal expands Innovent’s global reach and creates a monetization path for its pipeline, though specific financial terms were not provided.

Analysis

Pfizer and Innovent agreed to a licensing, co-development, and co-commercialization partnership across a portfolio of antibody-drug conjugates. Innovent will co-commercialize in the U.S. and Europe and share profits, while retaining rights in Greater China. The deal expands Innovent’s global reach and creates a monetization path for its pipeline, though specific financial terms were not provided.